Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), RaySearch Laboratories AB's 3-1 Month Momentum % is 27.69%.
The industry rank for RaySearch Laboratories AB's 3-1 Month Momentum % or its related term are showing as below:
CHIX:RAYBs's 3-1 Month Momentum % is ranked worse than 58.3% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: -1.52
vs CHIX:RAYBs: 27.69
RaySearch Laboratories AB (CHIX:RAYBs) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
RaySearch Laboratories AB 3-1 Month Momentum % Related Terms
CHIX:RAYBS vs VEEV, BTSG, HQY: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's 3-1 Month Momentum % falls into.
RaySearch Laboratories AB (CHIX:RAYBs) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (CHIX:RAYBS) has a 3-1 Month Momentum % of 27.69% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on RaySearch Laboratories AB and its competitors. According to the industry distribution chart, RaySearch Laboratories AB ranks #390 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 58.3%.
Is RaySearch Laboratories AB's 3-1 Month Momentum % too high?
RaySearch Laboratories AB's current 3-1 Month Momentum % is 27.69%. Based on the distribution chart, RaySearch Laboratories AB ranks #390 out of 669 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #390 out of 669 companies for 3-1 Month Momentum %. This places RaySearch Laboratories AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current 3-1 Month Momentum % is 27.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Fairly Valued. The stock's GF Value™ is kr231.47, compared to a current price of kr234.70 — trading 1.4% above its estimated fair value. The current 3-1 Month Momentum % is 27.69%. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current 3-1 Month Momentum % is 27.69% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 1.4% above its estimated GF Value™ of kr231.47.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for CHIX:RAYBS:
3-1 Month Momentum %: 27.69%
GF Value™: kr231.47 vs. price of kr234.70 (1.4% above fair value)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
